We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+16.34%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.75B
AUM Growth
+$551M
Cap. Flow
+$76.2M
Cap. Flow %
1.6%
Top 10 Hldgs %
42.9%
Holding
172
New
17
Increased
41
Reduced
66
Closed
24

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$190M
2
INSM icon
Insmed
INSM
+$168M
3
GILD icon
Gilead Sciences
GILD
+$130M
4
UTHR icon
United Therapeutics
UTHR
+$105M
5
BBIO icon
BridgeBio Pharma
BBIO
+$81.5M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$121M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.6M
3
RVMD icon
Revolution Medicines
RVMD
+$72.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$70.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$63.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Technology 0.03%
3 Communication Services 0.01%
4 Consumer Discretionary 0.01%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBNX
101
Beta Bionics
BBNX
$800M
$1.13M 0.02%
72,152
– –
LEGN icon
102
Legend Biotech
LEGN
$3.91B
$955K 0.02%
33,054
-2,832
-8% -$76.4K
PFE icon
103
Pfizer
PFE
$153B
$925K 0.02%
38,431
-69,204
-64% -$1.81M
ABVX
104
Abivax
ABVX
$10.4B
$852K 0.02%
6,397
+5,349
+510% +$605K
EHC icon
105
Encompass Health
EHC
$12.2B
$703K 0.01%
6,951
-2,878
-29% -$298K
AXSM icon
106
Axsome Therapeutics
AXSM
$11.3B
$658K 0.01%
2,689
-492
-15% -$107K
CERT icon
107
Certara
CERT
$1.23B
$651K 0.01%
99,442
– –
AGMB
108
AgomAb Therapeutics NV
AGMB
$653M
$639K 0.01%
49,248
-752
-2% -$8.46K
PRAX icon
109
Praxis Precision Medicines
PRAX
$10.2B
$618K 0.01%
1,847
+90
+5% +$28.5K
AAPL icon
110
Apple
AAPL
$4.46T
$541K 0.01%
1,768
-1,552
-47% -$444K
GRMN
111
Garmin
GRMN
$60B
$469K 0.01%
1,976
+655
+50% +$159K
DNLI icon
112
Denali Therapeutics
DNLI
$3.91B
$457K 0.01%
17,766
– –
GDX icon
113
VanEck Gold Miners ETF
GDX
$27.4B
$434K 0.01%
5,750
– –
MANE
114
Veradermics Inc
MANE
$4.7B
$426K 0.01%
+3,468
New +$325K
GOOGL icon
115
Alphabet (Google) Class A
GOOGL
$4.22T
$396K 0.01%
907
+593
+189% +$213K
DFTX
116
Definium Therapeutics
DFTX
$5.68B
$395K 0.01%
+8,391
New +$207K
TVTX icon
117
Travere Therapeutics
TVTX
$5.85B
$392K 0.01%
6,908
-1,991
-22% -$88.3K
AMZN icon
118
Amazon
AMZN
$2.84T
$383K 0.01%
1,605
+252
+19% +$63.3K
HALO icon
119
Halozyme
HALO
$11.2B
$340K 0.01%
4,348
+491
+13% +$33.5K
ALNY icon
120
Alnylam Pharmaceuticals
ALNY
$30.5B
$329K 0.01%
1,092
-233,451
-100% -$70.4M
CRSP icon
121
CRISPR Therapeutics
CRSP
$5.14B
$317K 0.01%
5,818
+802
+16% +$42.3K
GPCR icon
122
Structure Therapeutics
GPCR
$3.82B
$256K 0.01%
4,762
-2,041
-30% -$90.3K
VTRS icon
123
Viatris
VTRS
$18.6B
$251K 0.01%
+15,778
New +$245K
MLYS icon
124
Mineralys Therapeutics
MLYS
$2.28B
$236K 0.01%
8,753
-20,621
-70% -$566K
SMMT icon
125
Summit Therapeutics
SMMT
$10.7B
$223K ﹤0.01%
15,279
-579
-4% -$10.3K
3 4
5
6 7

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bellevue Group's Q2 2026 Portfolio in Review

As of Q2 2026, Bellevue Group held 172 positions worth $4.75B, up 13% from $4.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Bellevue Group's Q2 2026 filing shows 17 new, 41 increased, 66 reduced and 24 closed positions. Its largest new stake was Avalyn Pharma: 1,350,000 shares worth $44.4M. The largest sale was Krystal Biotech, an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Communication Services.

  • Bellevue Group's largest Q2 2026 buy was Avalyn Pharma: 1,350,000 shares worth $44.4M.
  • Bellevue Group added most to Amgen in Q2 2026, an estimated $190M increase.
  • Bellevue Group's biggest Q2 2026 reduction was Krystal Biotech, cutting an estimated $121M.
  • Bellevue Group fully exited Edgewise Therapeutics in Q2 2026, selling an estimated $48.1M.
  • Bellevue Group's ten largest holdings make up 43% of its $4.75B portfolio in Q2 2026.
  • Bellevue Group opened 17 new positions and closed 24 in Q2 2026.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.